Aspira Women's Health Inc. Stock: price and insider trades · United States

From a competitive standpoint, Aspira operates in a highly challenging women’s health diagnostics market where clinicians still have multiple conventional decision-making options and may not always order a specialized assay. Management identifies both traditional clinical pathways and specific competitors such as Fujirebio Diagnostics’ FDA-cleared ROMA test as meaningful competitive pressures on the Ova1Plus workflow. As a result, Aspira’s commercial strategy relies on demonstrating clinical utility, building physician adoption, and expanding reimbursement and distribution pathways. ([sec.gov](https://www.sec.gov/Archives/edgar/data/926617/000092661726000020/awhl-20251231x10k.htm))

Geographically, the company’s commercial footprint is primarily U.S.-national rather than international. It sells through a direct national sales force, including field sales and inside sales, markets tests directly to physicians through referral channels, and reaches laboratories via the Aspira Synergy platform. It also works with channel partners such as BioReference Health and ARUP, and in late 2024 expanded its BioReference collaboration to include OvaWatch, which suggests a continued push to deepen U.S. penetration through partner-led distribution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/926617/000092661726000020/awhl-20251231x10k.htm))

Recent developments underscore a company in transition. Aspira was notified in April 2025 that Nasdaq would delist its shares for failure to maintain the minimum stockholders’ equity requirement, after which the 2024 at-the-market program was terminated. In September 2025, the company completed a private placement with existing and new accredited investors, including board members. In its 2025 annual report, Aspira also said it remediated a previously identified material weakness in internal control over financial reporting by year-end 2025, and it highlighted its selection by ARPA-H for the Sprint for Women’s Health program in October 2024. ([sec.gov](https://www.sec.gov/Archives/edgar/data/926617/000092661725000008/awhl-20250930x10q.htm?utm_source=openai))